PT  - JOURNAL ARTICLE
AU  - Josep Font
AU  - Manuel Ramos-Casals
AU  - Gloria de la Red
AU  - Adolf Pou
AU  - Arnau Casanova
AU  - Mario García-Carrasco
AU  - Ricard Cervera
AU  - José A Molina
AU  - Josep Valls
AU  - Albert Bové
AU  - Miguel Ingelmo
AU  - Francesc Graus
TI  - Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature.
DP  - 2003 Jul 01
TA  - The Journal of Rheumatology
PG  - 1552--1557
VI  - 30
IP  - 7
4099  - http://www.jrheum.org/content/30/7/1552.short
4100  - http://www.jrheum.org/content/30/7/1552.full
SO  - J Rheumatol2003 Jul 01; 30
AB  - OBJECTIVE: To study the clinical course, response to therapy, and longterm outcome of pure sensory neuropathy (PSN) in a series of patients with primary Sjögren's syndrome (SS) followed prospectively in our referral centers. METHODS: We studied 15 patients (13 women, 2 men) with primary SS and PSN. All patients fulfilled 4 or more of the European diagnostic criteria. RESULTS: At diagnosis of PSN, clinical manifestations included numbness and paresthesias (11 patients), trigeminal neuropathy (6 patients), and Adie's pupil syndrome (4 patients). In 7 patients, PSN was diagnosed prior to SS, in 5 the diagnoses were made simultaneously, and in the remaining 3 patients PSN was diagnosed after the appearance of SS symptomatology. The mean duration of the prospective PSN followup was 10 years (range 1-20). The progression of PSN was acute in 1 patient (producing severe dysfunction in less than 1 month), subacute in 3 patients, and in the remaining 11, the symptoms progressed slowly over the ensuing years to other extremities. Patients were treated with corticosteroids (n = 13), cyclophosphamide (n = 4), and intravenous immunoglobulins (n = 1), and 2 patients received no treatment. In spite of treatment, most patients showed an indolent and insidious longterm PSN course. CONCLUSION: We found 3 differentiated clinical courses of the PSN in patients with primary SS: subacute progression in less than 1 month (7%), late acceleration of PSN 2-4 years after an initial indolent onset (20%), and a very longterm insidious, chronic evolution (73%). Prospective analysis of the longterm course of PSN shows a chronic and insidious evolution in most patients with PSN and SS, with a poor response to treatment, although stabilization of symptomatology for long periods is often observed.